TRCT
CTNM

Tower Research Capital (TRC)’s Contineum Therapeutics CTNM Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5K Buy
2,164
+1,433
+196% +$18.8K ﹤0.01% 3037
2026
Q1 		$9.55K Buy
731
+607
+490% +$8.14K ﹤0.01% 3924
2025
Q4 		$1.42K Sell
124
-1,551
-93% -$17.7K ﹤0.01% 4696
2025
Q3 		$19.7K Sell
1,675
-5,780
-78% -$46.6K ﹤0.01% 3324
2025
Q2 		$29.6K Buy
7,455
+6,097
+449% +$26.5K ﹤0.01% 3404
2025
Q1 		$9.48K Buy
1,358
+415
+44% +$3.77K ﹤0.01% 3769
2024
Q4 		$13.8K Buy
943
+463
+96% +$7.33K ﹤0.01% 3504
2024
Q3 		$9.19K Buy
480
+386
+411% +$7.4K ﹤0.01% 3893
2024
Q2 		$1.66K Buy
+94
New +$1.51K ﹤0.01% 5116

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tower Research Capital (TRC)'s CTNM Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Contineum Therapeutics (CTNM) stake by 196% in Q2 2026, buying an estimated $18.8K and bringing the position to 2,164 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3037.

Tower Research Capital (TRC) first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Tower Research Capital (TRC) held 2,164 shares of Contineum Therapeutics worth $35.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,433 Contineum Therapeutics shares in Q2 2026, an estimated $18.8K.
  • Contineum Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3037 holding.
  • Tower Research Capital (TRC) first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.